----item----
version: 1
id: {115BFA61-5999-4B51-9967-B926BD5C6480}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/15/BARDA Extends Chimerix Smallpox Contract Adds 13m
parent: {60DD0A61-687E-4825-852F-A2FA9D0FA023}
name: BARDA Extends Chimerix Smallpox Contract Adds 13m
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 957acf5d-baa7-418c-90f1-ea3c4e5a7977

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 51

BARDA Extends Chimerix Smallpox Contract; Adds $13m
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 49

BARDA Extends Chimerix Smallpox Contract Adds 13m
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1231

<p>The Biomedical Advanced Research and Development Authority (BARDA) has extended Chimerix contract to develop its oral antiviral brincidofovir as a medical countermeasure to treat smallpox for an additional 15 months, adding $13m more in funding.</p><p>The company's shares, however, failed to gain on the news &ndash; with the stock losing 4.2%, before closing at $51.14, down $1.08, or about 2%.</p><p>Chimerix received an initial award from BARDA in February 2011 to support the early research and development of brincidofovir in animal models of smallpox.</p><p>Then <a href="http://www.scripintelligence.com/policyregulation/BARDA-adds-17m-to-Chimerix-smallpox-contract-353684" target="_new">last September</a>, the company picked up an additional $17m to support Phase III trials.</p><p>Chimerix also is developing brincidofovir as a treatment to prevent cytomegalovirus in hematopoietic cell transplant recipients and also for adenovirus infection.</p><p>Last year, the company had pursued brincidofovir as a treatment for Ebola, but <a href="http://www.scripintelligence.com/home/Chimerix-abandons-Ebola-trials-of-brincidofovir-356478" target="_new">abandoned</a> that program this past February.</p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 252

<p>The Biomedical Advanced Research and Development Authority (BARDA) has extended Chimerix contract to develop its oral antiviral brincidofovir as a medical countermeasure to treat smallpox for an additional 15 months, adding $13m more in funding.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 49

BARDA Extends Chimerix Smallpox Contract Adds 13m
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150915T054208
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150915T054208
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150915T054208
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029764
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 51

BARDA Extends Chimerix Smallpox Contract; Adds $13m
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360361
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042449Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

957acf5d-baa7-418c-90f1-ea3c4e5a7977
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042449Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
